Dentsply Sirona appoints Matthew Garth as CFO, effective May 30, 2025

DENTSPLY SIRONA Inc.

Matthew Garth named EVP & CFO; previously CFO & CAO of Scotts Miracle-Gro.
Compensation: $800k base salary, 85% target bonus, annual equity grant of $2.75M.
Equity components: stock options ($687.5k), RSUs ($687.5k), PRSUs ($1.375M) with 3-year targets.
Nearly 30 years of financial leadership at Scotts, Minerals Technologies, and Alcoa.
No family relationships or material transactions disclosed; subject to non-compete and severance plan.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew E. Garth

Executive Vice President & Chief Financial Officer

XRAY · DENTSPLY SIRONA Inc.

Effective: 2025-05-30
Filed: May 29, 2025, 7:59 PM ET

On May 27, 2025, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed Matthew E. Garth as the Company’s Executive Vice President & Chief Financial Officer, effective as of May 30, 2025 (the “Effective Date”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Matthew E. Garth was appointed as Executive Vice President & Chief Financial Officer at DENTSPLY SIRONA Inc..

Action: appointed
Role: Executive Vice President & Chief Financial Officer

Exact text from the filing

On May 27, 2025, the Board of Directors (the “Board”) of DENTSPLY SIRONA Inc. (the “Company”) appointed Matthew E. Garth as the Company’s Executive Vice President & Chief Financial Officer, effective as of May 30, 2025 (the “Effective Date”).

View on SEC.gov

DENTSPLY SIRONA Inc. filing history →

Source: SEC EDGAR

accession 0000818479-25-000086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.